The effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer settings

Clin Adv Hematol Oncol. 2022 Sep;20(9):552-555.
No abstract available

Publication types

  • Interview

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Neoadjuvant Therapy

Substances

  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors